A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Summary

Single centre, single arm, preoperative window of opportunity study with a biomarker endpoint (expression profiling by RNA sequencing). Patients with resectable, histologically confirmed head and neck squamous cell carcinoma (HNSCC) for whom surgical treatment is planned as definitive management will be eligible.

Timeline

Start

2017-10-20

Primary completion

2021-09-13

Completion

2025-11-26

Publications

• Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kalpha inhibition in controlling tumor growth. Int J Cancer. 2019 Oct 15;145(8):2100-2106. doi: 10.1002/ijc.32009. Epub 2018 Dec 18.

Drugs

Indications